AFT Licenses Maxigesic(R) IV in Brazil

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com








01 May 2024
AFT Licenses Maxigesic
®
IV in Brazil.
AFT Pharmaceuticals (NZX: AFT, ASX: AFP) today announces the licensing of
Maxigesic IV, the intravenous form of its proprietary pain relief medicine, for
Brazil, the largest pharma market in South America and the

tenth largest
pharma market in the world
1
.
AFT Pharmaceuticals Managing Director Dr Hartley Atkinson said: “We are
delighted to announce our partnership with Brazil’s Halex Istar, an established
hospital injectables focused company. It is the ideal partner for this market, the
most significant in Latin America and one of the most important markets
globally.”
Tiago Salinas, CEO of Halex Istar, said: “We are similarly excited to be
establishing this partnership with AFT Pharmaceuticals, to be exclusively
responsible for distributing its Maxigesic IV [Paracetamol with Ibuprofen] in
Brazil. This helps Halex Istar to further strengthen its commitment to provide, to
the Brazilian hospital pharmaceutical sector, innovative products of
excellence. The medicine also complements our current multimodal analgesia
portfolio”.
AFT has now out-licensing or its own distribution arrangements for Maxigesic IV
in eight of the top Pharma markets in the world: USA, Germany, France, Italy,
UK (AFT Pharma UK Ltd), Canada (AFT Pharma Canada Ltd), Spain and now
Brazil. Dr Atkinson said, “We are pleased on the Maxigesic IV progress with
launches now in 36 countries around the globe”.

Footnote
1.https://www.statista.com/statistics/245473/market-share-of-the-leading-10-global-
pharmaceutical-markets/

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial
Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643

AFT Pharmaceuticals Limited,
Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN:
ARBN 609 017 969 investor.relations@aftpharm.com

Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets, and
distributes a broad portfolio of pharmaceutical products across a wide range of
therapeutic categories which are distributed across all major pharmaceutical
distribution channels: over the counter (OTC), prescription and hospital. Our product
portfolio comprises both proprietary and in-licensed products, and includes patented,
branded, and generic drugs
1
. Our business model is to develop and in-license
products for sale by our own dedicated sales teams in our home markets of Australia
and New Zealand and in certain Southeast Asian markets, and to out-license our
products to local licensees and distributors to over 125 countries around the world. For
more information about the company, visit our website www.aftpharm.com.

About Halex Istar
Halex Istar is one of the most relevant pharmaceutical companies in Brazil focused
on the hospital sector, building up a significant business over 50 years. Based on
pioneering and developing (being also responsible for launching Paracetamol
injectable in Brazil), Halex Istar also stands out for constant pursuit of innovation and
improvement for its products offered in the entire Brazilian territory with an injectable
ready-to-use portfolio (including therapeutic classes such as analgesics, antibiotics,
anti-inflammatory agents, and others) and medical devices. www.halexistar.com.br